English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/59438
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

AuthorsMitsiades, C. S.; Ocio, Enrique M. ; Pandiella, Atanasio ; Maiso, Patricia; Gajate, Consuelo; Garayoa, Mercedes ; Vilanova, David; Montero, Juan Carlos ; Mollinedo, Faustino ; San Miguel, Jesús F.
Issue Date2008
PublisherAmerican Association for Cancer Research
CitationCancer Research 68(13): 5216-5225 (2008)
AbstractDespite recent progress in its treatment, multiple myeloma (MM) remains incurable, thus necessitating identification of novel anti-MM agents. We report that the marine-derived cyclodepsipeptide Aplidin exhibits, at clinically achievable concentrations, potent in vitro activity against primary MM tumor cells and a broad spectrum of human MM cell lines, including cells resistant to conventional (e.g., dexamethasone, alkylating agents, and anthracyclines) or novel (e.g., thalidomide and bortezomib) anti-MM agents. Aplidin is active against MM cells in the presence of proliferative/antiapoptotic cytokines or bone marrow stromal cells and has additive or synergistic effects with some of the established anti-MM agents. Mechanistically, a short in vitro exposure to Aplidin induces MM cell death, which involves activation of p38 and c-jun NH2-terminal kinase signaling, Fas/CD95 translocation to lipid rafts, and caspase activation. The anti-MM effect of Aplidin is associated with suppression of a constellation of proliferative/antiapoptotic genes (e.g., MYC, MYBL2, BUB1, MCM2, MCM4, MCM5, and survivin) and up-regulation of several potential regulators of apoptosis (including c-JUN, TRAIL, CASP9, and Smac). Aplidin exhibited in vivo anti-MM activity in a mouse xenograft model. The profile of the anti-MM activity of Aplidin in our preclinical models provided the framework for its clinical testing in MM, which has already provided favorable preliminary results. ©2008 American Association for Cancer Research.
URIhttp://hdl.handle.net/10261/59438
DOI10.1158/0008-5472.CAN-07-5725
Identifiersdoi: 10.1158/0008-5472.CAN-07-5725
issn: 0008-5472
e-issn: 1538-7445
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.